SLC5A2 and hydrops fetalis: The pharmacological treatment of chronic HFrEF is now based on four classes of drugs that have been proven to reduce mortality among HF patients: ACE inhibitors or angiotensin II receptor blockers (ARBs), beta-blockers, aldosterone antagonists and SGLT2-inhibitors [16].